1. Fowler MG, Aizire J, Sikorskii A, Atuhaire P, et al.
   Growth deficits in antiretroviral and HIV exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months-of-age.
   AIDS 2021.
   


2. Munoz-Moreno JA, Carrillo-Molina S, Martinez-Zalacain I, Miranda C, et al.
   Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy.
   AIDS 2021.
   


3. Durstenfeld MS, Sun K, Ma Y, Rodriguez F, et al.
   Association of human immunodeficiency virus infection with outcomes among adults hospitalized with COVID-19.
   AIDS 2021.
   


4. Jeudy J, Patel P, George N, Burrowes S, et al.
   Assessment of coronary inflammation in antiretroviral treated people living with HIV infection and active HIV/HCV co-infection.
   AIDS 2021.
   


5. Cachay ER, Hasteh F, Mathews WC.
   Using computer-assisted content analysis to advance anal dysplasia natural history research: a validation study.
   AIDS 2021.
   


6. Birabaharan M, Strunk A, Kaelber DC, Smith DM, et al.
   Sex differences in type 2 diabetes mellitus prevalence among persons with HIV: a cross-sectional analysis.
   AIDS 2021.
   


7. Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, et al.
   Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study.
   AIDS 2021.
   


8. Neary J, Langat A, Singa B, Kinuthia J, et al.
   Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya.
   AIDS 2021.
   


9. Althoff KN, Stewart CN, Humes E, Zhang J, et al.
   The shifting age distribution of people with HIV using antiretroviral therapy in the United States, 2020 to 2030.
   AIDS 2021.
   


10. Ulfhammer G, Eden A, Antinori A, Brew BJ, et al.
    Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study.
    Clin Infect Dis 2021.
    


11. Pilarowski G, Marquez C, Rubio L, Peng J, et al.
    Field performance and public health response using the BinaxNOW TM Rapid SARS-CoV-2 antigen detection assay during community-based testing.
    Clin Infect Dis 2020.
    


12. Kojima N, Klausner JD.
    Patients may accurately self-collect pharyngeal and rectal specimens for Neisseria gonorrhoeae and Chlamydia trachomatis infection: But is there benefit?
    Clin Infect Dis 2020.
    


13. Woreta TA, Chalasani N.
    Fatty Liver Disease in Human Immunodeficiency Virus-Hepatitis B Virus Coinfection: A Cause for Concern.
    Clin Infect Dis 2021;73:e3286-e3287.
    


14. Khalili M, King WC, Kleiner DE, Jain MK, et al.
    Fatty Liver Disease in a Prospective North American Cohort of Adults with HIV and Hepatitis B Coinfection.
    Clin Infect Dis 2020.
    


15. McCallum AD, Pertinez HE, Else LJ, Dilly-Penchala S, et al.
    Intrapulmonary pharmacokinetics of first-line anti-TB drugs in Malawian tuberculosis patients.
    Clin Infect Dis 2020.
    


16. Ansari R, Rosen LB, Lisco A, Gilden D, et al.
    Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections.
    Clin Infect Dis 2021;73:e2705-e2712.
    


17. Moosa MS, Maartens G, Gunter H, Allie S, et al.
    A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.
    Clin Infect Dis 2020.
    


18. Mortimer TD, Pathela P, Crawley A, Rakeman JL, et al.
    The Distribution and Spread of Susceptible and Resistant Neisseria gonorrhoeae Across Demographic Groups in a Major Metropolitan Center.
    Clin Infect Dis 2021;73:e3146-e3155.
    


19. Campbell JR, Al-Jahdali H, Bah B, Belo M, et al.
    Safety and Efficacy of Rifampin or Isoniazid Among People with Mycobacterium tuberculosis Infection and Living with HIV or Other Health Conditions: Post-Hoc Analysis of Two Randomized Trials.
    Clin Infect Dis 2020.
    


20. Martinez L, Woldu H, Chen C, Hallowell BD, et al.
    Transmission Dynamics in Tuberculosis Patients with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis of 32 Observational Studies.
    Clin Infect Dis 2020.
    


21. Weinberg A, Aaron L, Montepiedra G, Sterling TR, et al.
    Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV.
    Clin Infect Dis 2020.
    


22. Jo Y, Shrestha S, Gomes I, Marks S, et al.
    Model-Based Cost-Effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York and Texas.
    Clin Infect Dis 2020.
    


23. Puyat JH, Shulha HP, Balshaw R, Campbell JR, et al.
    How well does TSTin3D predict risk of active tuberculosis in the Canadian immigrant population? An External Validation Study.
    Clin Infect Dis 2020.
    


24. Wilson EC, Turner CM, Sanz-Rodriguez C, Arayasirikul S, et al.
    Expanding the Pie-Differentiated PrEP Delivery Models to Improve PrEP Uptake in the San Francisco Bay Area.
    J Acquir Immune Defic Syndr 2021;88:S39-S48.
    


25. Sevelius JM, Glidden DV, Deutsch M, Welborn L, et al.
    Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California.
    J Acquir Immune Defic Syndr 2021;88:S27-S38.
    


26. Rice E, Wilder B, Onasch-Vera L, DiGuiseppi G, et al.
    A Peer-Led, Artificial Intelligence-Augmented Social Network Intervention to Prevent HIV Among Youth Experiencing Homelessness.
    J Acquir Immune Defic Syndr 2021;88:S20-S26.
    


27. Holloway IW, Beltran R, Shah SV, Cordero L, et al.
    Structural Syndemics and Antiretroviral Medication Adherence Among Black Sexual Minority Men Living With HIV.
    J Acquir Immune Defic Syndr 2021;88:S12-S19.
    


28. Arnold EA, Saberi P, Wong JO, Pollack LM, et al.
    We are Family: A Feasibility and Acceptability Study of an HIV Prevention Intervention With the House Ball and Gay Family Communities.
    J Acquir Immune Defic Syndr 2021;88:S6-S11.
    


29. Lightfoot M, Milburn N, Loeb Stanga L.
    Addressing Health Disparities in HIV: Introduction to the Special Issue.
    J Acquir Immune Defic Syndr 2021;88:S1-S5.
    


30. Lorenz DR, Mukerji SS, Misra V, Uno H, et al.
    Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr 2021;88:518-527.
    


31. Supanan R, Han WM, Harnpariphan W, Ueaphongsukkit T, et al.
    Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    J Acquir Immune Defic Syndr 2021;88:465-469.
    


32. Wagner Z, Mukasa B, Nakakande J, Stecher C, et al.
    Impact of the COVID-19 Pandemic on Use of HIV Care, Antiretroviral Therapy Adherence, and Viral Suppression: An Observational Cohort Study From Uganda.
    J Acquir Immune Defic Syndr 2021;88:448-456.
    


33. Friedman MR, Kempf MC, Benning L, Adimora AA, et al.
    Prevalence of COVID-19-Related Social Disruptions and Effects on Psychosocial Health in a Mixed-Serostatus Cohort of Men and Women.
    J Acquir Immune Defic Syndr 2021;88:426-438.
    


34. Ekstrand ML, Heylen E, Gandhi M, Steward WT, et al.
    COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns.
    J Acquir Immune Defic Syndr 2021;88:421-425.
    


35. Chai PR, Mohamed Y, Bustamante MJ, Goodman GR, et al.
    DigiPrEP: A pilot trial to evaluate the feasibility, acceptability, and accuracy of a digital pill system to measure PrEP adherence in men who have sex with men who use substances.
    J Acquir Immune Defic Syndr 2021.
    


36. Capoferri AA, Redd AD, Gocke CD, Clark LR, et al.
    Rebound HIV viremia with meningoencephalitis following antiretroviral therapy interruption after allogeneic bone marrow transplant.
    J Acquir Immune Defic Syndr 2021.
    


37. Calza L, Legnani G, Fulgaro C, Verucchi G, et al.
    CHANGES IN SERUM INFLAMMATORY MARKERS IN ANTIRETROVIRAL THERAPY-NAIVE HIV-INFECTED PATIENTS STARTING DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR.
    J Acquir Immune Defic Syndr 2021.
    


38. Ciccullo A, D'Angelillo A, Iannone V, Farinacci D, et al.
    Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV.
    J Acquir Immune Defic Syndr 2021;88:e5-e6.
    


39. Stockdale AJ, Meiring JE, Shawa IT, Thindwa D, et al.
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis 2021.
    


40. Popovich KJ.
    Using Genomic Sequencing to Delineate Community Networks of Methicillin-Resistant Staphylococcus aureus Transmission Among Men Who Have Sex With Men.
    J Infect Dis 2021;223:543-546.
    


41. Vieira VA, Adland E, Grayson NE, Csala A, et al.
    Two distinct mechanisms leading to loss of virological control in the rare group of antiretroviral therapy-naive, transiently aviraemic children living with HIV.
    J Virol 2021.
    


42. Chen J, Zhao S, Cui Z, Li W, et al.
    MicroRNA-376b-3p Promotes Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Restriction Factor TRIM22.
    J Virol 2021.
    


43. .
    Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet 2021;398:1593-1618.
    


44. Falcaro M, Castanon A, Ndlela B, Checchi M, et al.
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet 2021.
    


45. Samarasekera U.
    Etheldreda Nakimuli-Mpungu: innovator in mental health.
    Lancet 2021;398:109.
    

Display articles in

• Abstract format
• Medline format